Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.

Employees

511

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-26 pm EST			5-day change	1st Jan Change
72.82 ^USD	+0.03%		-.--%	+0.96%

Mar. 02	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from S&P Global BMI Index	CI
Mar. 02	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from S&P Biotechnology Select Industry Index	CI

Capitalization	11.3B 9.88B 8.92B 8.53B 15.52B 1,045B 16.14B 107B 42.24B 499B 42.4B 41.5B 1,803B	P/E ratio 2026 *	-	P/E ratio 2027 *	-
Enterprise value	11.3B 9.88B 8.92B 8.53B 15.52B 1,045B 16.14B 107B 42.24B 499B 42.4B 41.5B 1,803B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	95.17%	Yield 2026 *	-	Yield 2027 *	-

Mar. 02	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from S&P Global BMI Index	CI
Mar. 02	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from S&P Biotechnology Select Industry Index	CI
Mar. 02	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from S&P TMI Index	CI
Mar. 01	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from Russell Small Cap Comp Growth Benchmark	CI
Mar. 01	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from Russell 3000E Growth Benchmark	CI
Mar. 01	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from Russell 3000 Growth Benchmark	CI
Mar. 01	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from Russell 2500 Growth Benchmark	CI
Mar. 01	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from Russell 2000 Growth Benchmark	CI
Mar. 01	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from Russell 2500 Value-Dynamic Index	CI
Mar. 01	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from Russell 2500 Growth-Dynamic Index	CI
Mar. 01	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from Russell 2000 Value-Dynamic Index	CI
Mar. 01	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from Russell 2000 Growth-Dynamic Index	CI
Mar. 01	Avidity Biosciences, Inc.(NasdaqGM:RNAM) dropped from Russell 2500 Dynamic Index	CI

Dec. 18	Evercore ISI Downgrades Avidity Biosciences to In Line From Outperform, Adjusts Price Target to $72 From $65	MT
Dec. 10	Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says	MT
Nov. 07	Chardan Downgrades Avidity Biosciences to Neutral From Buy	MT
25-10-29	Wolfe Research Downgrades Avidity Biosciences to Peer Perform From Outperform	MT
25-10-29	TD Cowen Downgrades Avidity Biosciences to Hold From Buy, Adjusts Price Target to $74 From $78	MT

Avidity Biosciences, Inc. Stock

Equities

RNA

US05370A1088

Pharmaceuticals

Valuation: Avidity Biosciences, Inc.

Chart: Avidity Biosciences, Inc.

Latest news: Avidity Biosciences, Inc.

Last Transcript: Avidity Biosciences, Inc.

Analysts' recommendations: Avidity Biosciences, Inc.

Press Releases: Avidity Biosciences, Inc.

News in other languages: Avidity Biosciences, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Avidity Biosciences, Inc.

Biopharmaceuticals

Financials

Company Profile

Income Statement and Estimates

Mar. 02	Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies	AQ
Mar. 02	Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy	AQ
Feb. 27	Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies	PR
Feb. 26	Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference	PR
Feb. 23	Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders	PR

Feb. 27	Bourse Zurich: le SMI finit en forme grâce aux poids lourds
Feb. 27	Novartis finalise l'acquisition d'Avidity Biosciences
Feb. 27	Novartis schliesst Übernahme von Avidity Biosciences ab
Feb. 04	Größter Patentverlust seit Jahren: Novartis stellt sich auf Gewinnrückgang ein
Feb. 03	Prévisions Novartis: à l'aube de pertes d'exclusivité

1 day	+0.03%
1 month	-0.07%
3 months	+1.34%
6 months	+81.05%
Current year	+0.96%

1 month	72.68	73.05
Current year	72	73.06
1 year	21.51	73.06
3 years	4.82	73.06
5 years	4.82	73.06
10 years	4.82	73.06

Manager	Title	Age	Since
John McKenna PSD	President	-	2026-02-26
Jaime S. Huertas SEC	Corporate Secretary	-	2026-02-26

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
AVIDITY BIOSCIENCES, INC.	+0.03%	-.--%	+134.07%	+243.81%	11.3B
REGENERON PHARMACEUTICALS, INC.	-0.11%	-1.85%	+11.83%	-1.91%	76.53B
UCB	-1.19%	-0.56%	+38.78%	+215.55%	54.36B
SAMSUNG BIOLOGICS CO.,LTD.	-2.03%	+59.20%	+59.20%	+59.20%	49.13B
CSL LIMITED	-0.09%	-0.86%	-43.12%	-51.26%	47.5B
BIOGEN INC.	-1.81%	-1.80%	+30.20%	-30.80%	26.64B
MODERNA, INC.	-1.55%	+0.08%	+51.82%	-64.87%	20.76B
INCYTE CORPORATION	+0.55%	-3.54%	+36.37%	+27.69%	18.42B
INNOVENT BIOLOGICS, INC.	-0.31%	-1.28%	+101.50%	+89.44%	17.92B
SWEDISH ORPHAN BIOVITRUM AB	-1.69%	-1.01%	+27.67%	+56.44%	13.66B
Average	-0.80%	-1.44%	+44.83%	+54.33%	33.62B
Weighted average by Cap.	-0.80%	-1.43%	+30.15%	+46.15%

	2026 *	2027 *
Net sales	-	-
Net income	-843M -737M -666M -637M -1.16B -77.98B -1.2B -7.95B -3.15B -37.25B -3.16B -3.1B -135B	-602M -526M -475M -455M -827M -55.66B -859M -5.68B -2.25B -26.59B -2.26B -2.21B -96.04B
Net Debt	-	-